Chicago-The traditional PSA cut-point of 4.0 ng/mL for recommending abiopsy to diagnose prostate cancer is controversial, and some researchershave recommended cut-points as low as 2.0 ng/mL. Two separate studies presentedat the AUA annual meeting here have found that cut-points of 2.5 or 2.6ng/mL may be more appropriate for determining the need for prostate biopsy.
Malpractice Consult: How likely are you to face a medical malpractice lawsuit?
July 23rd 2024"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
UK study of AI-based software for prostate cancer detection expands
July 22nd 2024"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and patients, and looking at the impact on workflow," says Clare Verrill, BM, FRCPath, MMedEd.